These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25010949)

  • 41. Risk factors for hypoglycemia in patients with type 2 diabetes, hospitalized in internal medicine wards: Findings from the FADOI-DIAMOND study.
    Borzì V; Frasson S; Gussoni G; Di Lillo M; Gerloni R; Augello G; Gulli G; Ceriello A; Solerte B; Bonizzoni E; Fontanella A;
    Diabetes Res Clin Pract; 2016 May; 115():24-30. PubMed ID: 27242119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
    Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
    Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
    Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
    Laakso M; Rosenstock J; Groop PH; Barnett AH; Gallwitz B; Hehnke U; Tamminen I; Patel S; von Eynatten M; Woerle HJ
    Diabetes Care; 2015 Feb; 38(2):e15-7. PubMed ID: 25614693
    [No Abstract]   [Full Text] [Related]  

  • 45. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis.
    Schopman JE; Simon AC; Hoefnagel SJ; Hoekstra JB; Scholten RJ; Holleman F
    Diabetes Metab Res Rev; 2014 Jan; 30(1):11-22. PubMed ID: 24030920
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Documented hypoglycemia is associated with poor short and long term prognosis among patients admitted to general internal medicine departments.
    Leibovitz E; Khanimov I; Wainstein J; Boaz M
    Diabetes Metab Syndr; 2019; 13(1):222-226. PubMed ID: 30641701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Hypoglycemia - frequency, causes, induced costs].
    Breuer HW; Ptak P
    Dtsch Med Wochenschr; 2012 May; 137(19):988-92. PubMed ID: 22549254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation between measures of hypoglycemia and glycemic improvement in sulfonylurea treated patients with type 2 diabetes in India: results from the OBSTACLE hypoglycemia study.
    Kalra S; Deepak MC; Narang P; Singh V; Maheshwari A
    J Postgrad Med; 2014; 60(2):151-5. PubMed ID: 24823514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.
    Francis M; Langhan T; Prosser J; Hoffman R
    Ann Emerg Med; 2008 Jun; 51(6):795-6; author reply 796-7. PubMed ID: 18489980
    [No Abstract]   [Full Text] [Related]  

  • 52. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.
    Umezawa S; Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Miyairi Y; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    BMC Endocr Disord; 2015 Jul; 15():34. PubMed ID: 26137940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent metformin adherence and the risk of hypoglycaemia in the year following intensification with a sulfonylurea.
    Min JY; Griffin MR; Chipman J; Hackstadt AJ; Greevy RA; Grijalva CG; Hung AM; Roumie CL
    Diabet Med; 2019 Apr; 36(4):482-490. PubMed ID: 30378161
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
    Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nyström T; Norhammar A
    Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristics and mortality of type 2 diabetic patients hospitalized for severe iatrogenic hypoglycemia.
    Fadini GP; Rigato M; Tiengo A; Avogaro A
    Diabetes Res Clin Pract; 2009 Jun; 84(3):267-72. PubMed ID: 19250694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
    Hirst JA; Farmer AJ; Dyar A; Lung TW; Stevens RJ
    Diabetologia; 2013 May; 56(5):973-84. PubMed ID: 23494446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing potential glycemic overtreatment in persons at hypoglycemic risk.
    Tseng CL; Soroka O; Maney M; Aron DC; Pogach LM
    JAMA Intern Med; 2014 Feb; 174(2):259-68. PubMed ID: 24322626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
    Christensen AS; Hædersdal S; Støy J; Storgaard H; Kampmann U; Forman JL; Seghieri M; Holst JJ; Hansen T; Knop FK; Vilsbøll T
    Diabetes Care; 2020 Sep; 43(9):2025-2033. PubMed ID: 32661107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.